|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1201 Maryland Avenue SW |
Address2 | Suite 900 |
| City | Washington |
State | DC |
Zip Code | 20024 |
Country | USA |
3. Principal place of business (if different than line 2)
| City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 6245-12
|
||||||||
|
6. House ID# 325050000
|
||||||||
| TYPE OF REPORT | 8. Year | 2008 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Brent DelMonte, Vice President for Federal Government Relations |
Date | 05/20/2008 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ACC
16. Specific lobbying issues
Sarbanes-Oxley Reform
Section 404
SEC and PCAOB Guidance on Auditing Standard (AS-5)
Financial Services and General Government Appropriations Act for FY 2009
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Paul |
Poteet |
|
|
|
Alan |
Eisenberg |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Patrick |
Carroll |
|
Legislative Assistant, Congressman LaHood |
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code AGR
16. Specific lobbying issues
Biofuels Tax Credit
Implementation of the Renewable Fuels, Consumer Protection and Energy Efficiency Act of 2007
H.R. 2419
Renewable Fuels Standard
Livestock Cloning/Product Labeling
FDA Risk Assessment on Cloning
USDA National Organic Program Advance Notice of Proposed Rulemaking
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for FY2009
H.R. 3161
S. 1859
H.R. 992
S. 414
H.R. 1396
S. 536
H.R. 4855
H.R. 2419
S. 2663l
2007 Farm Bill (H.R. 2419)
Biofuels Tax Credit
USDA Administrative Proposals
Livestock Cloning/Product Labeling
Importation of Plant Products
Biomass Energy Reserve/Biomass Crop Transition Program
Bio-based Product "BioPreferred" Procurement Program
Foreign Agricultural Biotechnology Laws and Regulations
U.S. Korea Free Trade Agreement
China Biotechnology Trade Negotiations
Mexico Biotechnology Trade Negotiations
Russia Biotechnology Trade Negotiations
Vietnam Biotechnology Negotiations
France Trade Meetings
French Ban on Cultivating of Biotech Seeds
EPA Regulation of Plant Incorporated Protectants
Proposed Rule
Adventitious Presence
U.S. Government Policy Position for Codex Guidelines on Adventitious Presence
Korea Trade Negotiations
EU Trade Meetings
World Trade Organization on EU Biotech Moratorium
Review of EU Labeling Regulations
Genetically Engineered (GE) Animals
FDA and USDA Regulation of GE Animals
Biotechnology Crop Stewardship
Policies Impacting Global Trade of Ag-Biotech Products
U.S. Government Positions
Cartagena Biosafety Protocol
U.S. Government Positions/Activities/Communications at Biosafety Protocol Meetings
Bio-based Products Tax Credits
USDA/APHIS Agricultural Biotechnology Regulations
USDA Rulemaking on 7 CFR 340
Restrictions on Importation of Plant Products/Lacey Act Amendments
H.R. 2419
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Environmental Protection Agency (EPA), Agriculture - Dept of (USDA), Food & Drug Administration (FDA), State - Dept of (DOS), U.S. Trade Representative (USTR), Commerce - Dept of (DOC), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), U.S. Agency for International Development (USAID)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brent |
Erickson |
|
|
|
Amy |
Ehlers |
|
|
|
Sharon |
Bomer Lauristen |
|
|
|
Bill |
Olson |
|
Legislative Assistant, Rep. John Shimkus |
|
Matt |
Carr |
|
|
|
Barbara |
Glenn |
|
|
|
Sarah |
Lukie |
|
|
|
Brent |
Del Monte |
|
|
|
Paul |
Poteet |
|
|
|
Patrick |
Carroll |
|
Legislative Assistant, Congressman LaHood |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ANI
16. Specific lobbying issues
Genetically Engineered (GE) Animals
FDA and USDA Regulation of GE Animals
Livestock Cloning/Product Labeling
FDA Risk Assessment on Cloning
USDA National Organic Program Advance Notice of Proposed Rulemaking
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for FY2009
H.R. 3161
S. 1859
H.R. 992
S. 414
H.R. 1396
S. 536
H.R. 4855
H. R. 2419
S. 2663l
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), U.S. Trade Representative (USTR), State - Dept of (DOS), Natl Economic Council (NEC), Commerce - Dept of (DOC)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Barbara |
Glenn |
|
|
|
Sharon |
Bomer Lauritsen |
|
|
|
Bill |
Olson |
|
Legislative Assistant, Rep. John Shimkus |
|
Brent |
Del Monte |
|
|
|
Patrick |
Carroll |
|
Legislative Assistant, Congressman LaHood |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for FY2009
Funding for the Food and Drug Administration (Human Drug Review, Biologics, Food Safety, Critical Path, Regan-Udall
Foundation, Center for Veterinary Medicine)
Cont....
Funding for the Department of Agriculture (Biotechnology Regulatory Services (APHIS), Animal Care &
Veterinary Services (APHIS), Trade Activities (Office of the Secretary & Food Safety Inspection Service) Agriculture
Research Service, Biofuels (Rural Development)
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY 2009
Funding for National Institutes of Health
Funding for Bioterrorism and Emergency Preparedness
Funding for Pandemic Influenza Preparedness
Funding for Biomedical Advanced Research & Development Authority (BARDA)
Energy and Water Development and Related Agencies Appropriations Act for FY 2009
Funding for Biofuels
Financial Services and General Government Appropriations Act for FY 2009
Sarbanes Oxley Reform
Commerce, Justice, Science, and Related Agencies Appropriations Act for FY 2009
Funding for Technology Innovation Program (TIP)
Department of State, Foreign Operations and Related Programs Appropriations Act for FY 2009
Funding for Biotechnology Research and Development Programs at the Agency for International Development
Department of the Interior, Environment, and Related Agencies Appropriations for FY 2009
Funding for the Environmental Protection Agency
17. House(s) of Congress and Federal agencies Check if None
Natl Institute of Standards & Technology (NIST), U.S. Agency for International Development (USAID), U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, White House Office, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Patrick |
Carroll |
|
Legislative Assistant, Congressman LaHood |
|
Sharon |
Bomer Lauritsen |
|
|
|
Christopher |
Colwell |
|
|
|
John |
Taylor |
|
|
|
Sara |
Radcliffe |
|
|
|
Tricia |
Brooks |
|
|
|
Andrew |
Emmett |
|
|
|
Jeanne |
Haggerty |
|
Policy Advisor, Congressman Joe Barton |
|
Eli |
Joseph |
|
|
|
Alan |
Eisenberg |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Patent Reform
H.R. 1908
S. 1145
CBD TRIPS Amendment
Patent Disclosure Requirements
PTO Proposed Regulations
Continuation Rules: FR 2005-P-066
Claims Rules: FR 2005-P-067
Information Disclosure Rules: 71-FR-38808
Alternative Claims Rule: 72-FR-154
Intellectual Property and Access to Medicines for Neglected Diseases and Diseases of Developing World
Bayh-Dole Act Evaluation
International Intellectual Property Enforcement
Anti-counterfeiting
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Patent & Trademark Office (PTO), Congressional Budget Office (CBO), State - Dept of (DOS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Health & Human Services - Dept of (HHS), Commerce - Dept of (DOC), U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Lila |
Feisee |
|
|
|
Hansjorg |
Sauer |
|
|
|
Tom |
DiLenge |
|
|
|
Tricia |
Brooks |
|
|
|
John |
Taylor |
|
|
|
Jeanne |
Haggerty |
|
Policy Advisor, Congressman Joe Barton |
|
Melissa |
Bowie |
|
|
|
Eli |
Joseph |
|
|
|
Susie |
Ahn |
|
|
|
Paul |
Poteet |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
Drug Safety
Implementation of Food & Drug Administration Amendments Act of 2007
Heparin Contamination/Imported Drugs and Drug Products
Counterfeit Drugs
Livestock Cloning/Product Labeling
FDA Risk Assessment on Cloning
USDA National Organic Program Advance Notice of Proposed Rulemaking
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for FY2009
H.R. 3161
S. 1859
H.R. 992
S. 414
H.R. 1396
S. 536
H.R. 4855
H. R. 2419
S. 2663l
Drug Importation
H.R. 3610
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for FY 2009
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY 2009
Department of Homeland Security Appropriations Act for FY 2009
Genetically Engineered (GE) Animals
FDA and USDA Regulation of GE Animals
Adventitious Presence
U.S. Government Policy Position for Codex Guidelines on Adventitious Presence
Korea Trade Negotiations
EU Trade Meetings
Imported Food Safety
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Agriculture - Dept of (USDA), U.S. Trade Representative (USTR), State - Dept of (DOS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Agriculture - Dept of (USDA), Commerce - Dept of (DOC), Office of Science & Technology Policy (OSTP)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Sara |
Radcliffe |
|
|
|
John |
Taylor |
|
|
|
Sharon |
Bomer Lauritsen |
|
|
|
Barbara |
Glenn |
|
|
|
Patrick |
Carroll |
|
Legislative Assistant, Congressman LaHood |
|
Sandra |
Dennis |
|
|
|
Bill |
Olson |
|
Legislative Assistant, Rep. John Shimkus |
|
Jeanne |
Haggerty |
|
Policy Advisor, Congressman Joe Barton |
|
Tom |
DiLenge |
|
|
|
Melissa |
Bowie Adkinson |
|
Chief Health Counsel, U.S. Senate HELP Com. |
|
Eli |
Joseph |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENG
16. Specific lobbying issues
Biofuels Tax Credit
H.R. 2419
Implementation of the Renewable Fuels, Consumer Protection and Energy Efficiency Act of 2007
2007 Farm Bill (H.R. 2419)
Biofuels Tax Credit
Biomass Energy Reserve/Biomass Crop Transition Program
Renewable Fuels Standard
Energy and Water Development and Related Agencies Appropriations Act for FY 2009
Funding for Biofuels
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Treasury - Dept of, Environmental Protection Agency (EPA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Matt |
Carr |
|
|
|
Amy |
Ehlers |
|
|
|
Brent |
Erickson |
|
|
|
Bill |
Olson |
|
Legislative Assistant, Rep. John Shimkus |
|
Paul |
Poteet |
|
|
|
Patrick |
Carroll |
|
Legislative Assistant, Congressman LaHood |
|
Paul |
Poteet |
|
|
|
Sharon |
Bomer Lauritsen |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FOO
16. Specific lobbying issues
Adventitious Presence
U.S. Government Policy Position for Codex Guidelines on Adventitious Presence
Korea Trade Negotiations
EU Trade Meetings
Genetically Engineered (GE) Animals
FDA and USDA Regulation of GE Animals
Livestock Cloning/Product Labeling
FDA Risk Assessment on Cloning
USDA National Organic Program Advance Notice of Proposed Rulemaking
H.R. 3161
S. 1859
H.R. 992
S. 414
H.R. 1396
S. 536
H.R. 4855
H.R. 2419
S. 2663l
Imported Food Safety
17. House(s) of Congress and Federal agencies Check if None
Agriculture - Dept of (USDA), Food & Drug Administration (FDA), State - Dept of (DOS), U.S. Trade Representative (USTR), U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Natl Economic Council (NEC), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Sharon |
Bomer Lauristen |
|
|
|
Barbara |
Glenn |
|
|
|
Bill |
Olson |
|
Legislative Assistant, Rep. John Shimkus |
|
Brent |
Del Monte |
|
|
|
John |
Taylor |
|
|
|
Tom |
DiLenge |
|
|
|
Paul |
Poteet |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FUE
16. Specific lobbying issues
Biofuels Tax Credit
Implementation of the Renewable Fuels, Consumer Protection and Energy Efficiency Act of 2007
H.R. 2419
Energy and Water Development and Related Agencies Appropriations Act for FY 2009
Funding for Biofuels
2007 Farm Bill (H.R. 2419)
Biofuels Tax Credit
Biomass Energy Reserve/Biomass Crop Transition Program
Renewable Fuels Standard
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Treasury - Dept of, Environmental Protection Agency (EPA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Matt |
Carr |
|
|
|
Amy |
Ehlers |
|
|
|
Brent |
Erickson |
|
|
|
Patrick |
Carroll |
|
Legislative Assistant, Congressman LaHood |
|
Bill |
Olson |
|
Legislative Assistant, Rep. John Shimkus |
|
Paul |
Poteet |
|
|
|
Sharon |
Bomer Lauristen |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Drug Safety
Implementation of Food & Drug Administration Amendments Act of 2007
Heparin Contamination/Imported Drugs and Drug Products
Counterfeit Drugs
Drug Importation
H.R. 3610
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY 2009
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for FY 2009
Department of Homeland Security Appropriations Act for FY 2009
Stem Cell Research
S.5
Medicaid Rebates
H.R. 1424
H. Con. Res. 312
S. Con. Res. 70
Senate Medicare Package
Human Growth Hormone Abuse
S. 877
H.R. 4911
340B of the Public Health Service Act/Drug Prices for Covered Entities
H.R. 2606
S. 1376
Follow-on Biologics
H.R. 1038
H.R. 1956
H.R. 5629
S. 1695
FDA Regulatory Processes for First-Time Filers
Biomedical Advanced Research & Development Authority (BARDA) Funding
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY 2009
Pandemic Influenza Preparedness Funding
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY 2009
Vaccine Financing
National Vaccine Advisory Committee Draft Recommendations
Vaccines for Children Program
National Vaccine Advisory Committee Draft Recommendations
Influenza Vaccine Supply and Immunization Recommendations
Barriers and Incentives Related to Personalized Medicine
Medicare Hospital Outpatient Drug Reimbursement Policies
In Vitro Diagnostics
Regulatory Oversight
Critical Path Initiative
Comparative Effectiveness Program Initiatives
H.R. 3162
H. Con. Res. 312
S. Con. Res. 70
Medicare Packages
Comparative Effectiveness Research Act of 2008
Funding for the Food and Drug Administration (Human Drug Review, Biologics, Food Safety, Critical Path, Regan-Udall
Foundation, Center for Veterinary Medicine)
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for FY 2009
International Market Access for U.S. Healthcare Products
Healthcare Sector Advocacy/Free Trade Agreements
Funding for National Institutes of Health
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY 2009
Funding for Bioterrorism and Emergency Preparedness
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY 2009
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), White House Office, Office of Science & Technology Policy (OSTP), Centers For Disease Control & Prevention (CDC), Commerce - Dept of (DOC), Treasury - Dept of
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Taylor |
|
|
|
Sara |
Radcliffe |
|
|
|
Patrick |
Carroll |
|
Legislative Assistant, Congressman LaHood |
|
Tricia |
Brooks |
|
|
|
Melissa |
Bowie Atkinson |
|
Chief Health Counsel, U.S. Senate, HELP Com. |
|
Susie |
Ahn |
|
|
|
Jeanne |
Haggerty |
|
Policy Advisor, Congressman Joe Barton |
|
Eli |
Joseph |
|
|
|
Sandra |
Dennis |
|
|
|
John |
Siracusa |
|
|
|
Edward |
Buckley |
|
|
|
E. Cartier |
Esham |
|
|
|
Christopher |
Colwell |
|
|
|
Paul |
Poteet |
|
|
|
Kelly |
Lai |
|
|
|
Andrew |
Emmett |
|
|
|
Tom |
DiLenge |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HOM
16. Specific lobbying issues
Pandemic Influenza Preparedness Funding
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY 2009
Influenza Vaccine Supply and Immunization Recommendations
Funding for Biomedical Advanced Research & Development Authority (BARDA)
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY 2009
Funding for Bioterrorism and Emergency Preparedness
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY 2009
Funding for Pandemic Influenza Preparedness
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY 2009
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), White House Office, Centers For Disease Control & Prevention (CDC)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Christopher |
Colwell |
|
|
|
Patrick |
Carroll |
|
Legislative Assistant, Congressman LaHood |
|
John |
Taylor |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Funding for Bioterrorism and Emergency Preparedness
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY 2009
Funding for National Institutes of Health
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY 2009
Funding for Biomedical Advanced Research & Development Authority (BARDA)
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY 2009
Funding for Pandemic Influenza Preparedness
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY 2009
Critical Path Initiative
Comparative Effectiveness Program Initiatives
H.R. 3162
H. Con. Res. 312
S. Con. Res. 70
Medicare Packages
Comparative Effectiveness Research Act of 2008
Stem Cell Research
S.5
In Vitro Diagnostics
Regulatory Oversight
Barriers and Incentives Related to Personalized Medicine
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), White House Office, Food & Drug Administration (FDA), Office of Science & Technology Policy (OSTP)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Eli |
Joseph |
|
|
|
Melissa |
Bowie Adkinson |
|
Chief Health Counsel, U.S. Senate HELP Com. |
|
Sara |
Radcliffe |
|
|
|
Tricia |
Brooks |
|
|
|
Sandra |
Dennis |
|
|
|
Christopher |
Colwell |
|
|
|
Patrick |
Carroll |
|
Legislative Assistant, Congressman LaHood |
|
John |
Siracusa |
|
|
|
John |
Taylor |
|
|
|
Eli |
Joseph |
|
|
|
Susie |
Ahn |
|
|
|
Jeanne |
Haggerty |
|
Policy Advisor, Congressman Joe Barton |
|
Tom |
DiLenge |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Medicaid Rebates
H.R. 1424
Senate Medicare Package
H. Con. Res 312 & S. Con. Res. 70
Medicare Hospital Outpatient Drug Reimbursement Policies
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Taylor |
|
|
|
Susie |
Ahn |
|
|
|
Jeanne |
Haggerty |
|
Policy Advisor, Congressman Joe Barton |
|
Sandra |
Dennis |
|
|
|
John |
Siracusa |
|
|
|
Eli |
Joseph |
|
|
|
Brent |
Del Monte |
|
|
|
Melissa |
Bowie Adkinson |
|
Chief Health Counsel, U.S. Senate, HELP Com. |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Medicaid Rebates
H.R. 1424
Senate Medicare Package
H. Con. Res 312 & S. Con. Res. 70
Medicare Hospital Outpatient Drug Reimbursement Policies
340B of the Public Health Service Act/Drug Prices for Covered Entities
H.R. 2606
S. 1376
Comparative Effectiveness Program Initiatives
H.R. 3162
H. Con. Res 312
S. Con. Res. 70
Medicare Packages
Comparative Effectiveness Research Act of 2008
Influenza Vaccine Supply and Immunization Recommendations
Drug Importation
H.R. 3610
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY 2009
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for FY 2009
Department of Homeland Security Appropriations Act for FY 2009
Drug Safety
Implementation of Food & Drug Administration Amendments Act
Heparin Contamination/Imported Drugs and Drug Products
Counterfeit Drugs
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), Centers For Medicare and Medicaid Services (CMS), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Taylor |
|
|
|
Sandra |
Dennis |
|
|
|
Eli |
Joseph |
|
|
|
Susie |
Ahn |
|
|
|
Tricia |
Brooks |
|
|
|
John |
Siracusa |
|
|
|
Melissa |
Bowie Adkinson |
|
Chief Health Counsel, U.S. Senate, HELP Com. |
|
Jeanne |
Haggerty |
|
Policy Advisor, Congressman Joe Barton |
|
Christopher |
Colwell |
|
|
|
Sara |
Radcliffe |
|
|
|
Tom |
DiLenge |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SCI
16. Specific lobbying issues
Stem Cell Research
S.5
Small Business Innovation and Research Program (SBIR)
Reauthorization Act
Venture-Backed Firm Eligibility
R&D Tax Credit
Extension of Expired R&D Tax Credit
Technology Innovation Program (TIP)
Proposed Rules
Funding
-Departments of Commerce, Justice, Science, and Related Agencies Appropriations Act for FY 2009
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Office of Science & Technology Policy (OSTP), Natl Economic Council (NEC), Commerce - Dept of (DOC)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tricia |
Brooks |
|
|
|
E. Cartier |
Esham |
|
|
|
Alan |
Eisenberg |
|
|
|
Paul |
Poteet |
|
|
|
Eli |
Joseph |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Tom |
DiLenge |
|
|
|
Susie |
Ahn |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SMB
16. Specific lobbying issues
Small Business Innovation and Research Program (SBIR)
Reauthorization Act
Venture-Backed Firm Eligibility
Sarbanes-Oxley Reform
Section 404
SEC and PCAOB Guidance on Auditing Standard (AS-5)
Financial Services and General Government Appropriations Act for FY 2009
FDA Regulatory Processes for First-Time Filers
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Office of Science & Technology Policy (OSTP), Natl Economic Council (NEC), Natl Institutes of Health (NIH), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
E. Cartier |
Esham |
|
|
|
Alan |
Eisenberg |
|
|
|
Paul |
Poteet |
|
|
|
Eli |
Joseph |
|
|
|
Tricia |
Brooks |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Sandra |
Dennis |
|
|
|
John |
Siracusa |
|
|
|
Patrick |
Carroll |
|
Legislative Assistant, Congressman LaHood |
|
Tom |
DiLenge |
|
|
|
Susie |
Ahn |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Biofuels Tax Credit
Implementation of the Renewable Fuels, Consumer Protection and Energy Efficiency Act of 2007
H.R. 2419
Bio-based Products Tax Credits
R&D Tax Credit
Extension of Expired R&D Tax Credit
Election of R&D/AMT Tax Credits in Lieu of Bonus Depreciation
S.12
H.R. 5140
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Treasury - Dept of, Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brent |
Erickson |
|
|
|
Matt |
Carr |
|
|
|
Amy |
Ehlers |
|
|
|
Paul |
Poteet |
|
|
|
Eli |
Joseph |
|
|
|
E. Cartier |
Esham |
|
|
|
Alan |
Eisenberg |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Cartagena Biosafety Protocol
U.S. Government Positions/Activities/Communications at Biosafety Protocol Meetings
Foreign Agricultural Biotechnology Laws and Regulations
U.S. Korea Free Trade Agreement
China Biotechnology Trade Negotiations
Mexico Biotechnology Trade Negotiations
Russia Biotechnology Trade Negotiations
Vietnam Biotechnology Negotiations
France Trade Meetings
French Ban on Cultivation of Biotech Seeds
Adventitious Presence
U.S. Government Policy Position for Codex Guidelines on Adventitious Presence
Korea Trade Negotiations
EU Trade Meetings
World Trade Organization on EU Biotech Moratorium
Review of EU Labeling Regulations
CBD TRIPS Amendment
Patent Disclosure Requirements
Intellectual Property and Access to Medicines for Neglected Diseases and Diseases of Developing World
Policies Impacting Global Trade of Ag-Biotech Products
U.S. Government Policies
International Market Access for U.S. Healthcare Products
Healthcare Sector Advocacy/Free Trade Agreements
Drug Importation
H.R. 3610
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for FY 2009
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act for FY 2009
Department of Homeland Security Appropriations Act for FY 2009
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), U.S. Trade Representative (USTR), State - Dept of (DOS), Agriculture - Dept of (USDA), Commerce - Dept of (DOC), Natl Economic Council (NEC), Patent & Trademark Office (PTO)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Patrick |
Carroll |
|
Legislative Assistant, Congressman LaHood |
|
John |
Taylor |
|
|
|
Sharon |
Bomer Lauritsen |
|
|
|
Sarah |
Lukie |
|
|
|
Lila |
Feisee |
|
|
|
Paul |
Poteet |
|
|
|
Kelly |
Lai |
|
|
|
Tom |
DiLenge |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CIV
16. Specific lobbying issues
Genetic Information Non-Discrimination Act
S. 358
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Melissa |
Bowie Atkinson |
|
Chief Counsel, U.S. Senate, HELP Com. |
|
Eli |
Joseph |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code GOV
16. Specific lobbying issues
False Claims Act Amendments
S.2041
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Sandra |
Dennis |
|
|
|
Eli |
Joseph |
|
|
|
Melissa |
Bowie Adkinson |
|
Chief Health Counsel, U.S. Senate, HELP Com. |
|
Tom |
DiLenge |
|
|
|
Brent |
Del Monte |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code LAW
16. Specific lobbying issues
Human Growth Hormone Abuse
S. 877
H.R. 4911
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Susie |
Ahn |
|
|
|
Eli |
Joseph |
|
|
|
Melissa |
Bowie Adkinson |
|
Chief Health Counsel, U.S. Senate HELP Com. |
|
Tom |
DiLenge |
|
|
|
Sandra |
Dennis |
|
|
|
Brent |
Del Monte |
|
|
|
Jeanne |
Haggerty |
|
Policy Advisor, Congressman Joe Barton |
|
John |
Taylor |
|
|
|
Sara |
Radcliffe |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address | |
||||||
| City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
| City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
5 |
|
||||||
| 2 |
|
6 |
|
||||||
| 3 |
|
7 |
|
||||||
| 4 |
|
8 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address: BIO maintains a list of all of its members on its website at http://bio.org/members/index.asp
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 3 | 5 |
| 2 | 4 | 6 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 5 | 9 |
| 2 | 6 | 10 |
| 3 | 7 | 11 |
| 4 | 8 | 12 |